Publication details
PCSK9 inhibitory – nové možnosti v léčbě hypercholesterolemie: U koho budou indikovány? Stanovisko České společnosti pro aterosklerózu
| Title in English | PCSK9 inhibitors – new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated? Czech atherosclerosis society statement |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Vnitřní lékařství |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | familial hypercholesterolemia; LDL-cholesterol; PCSK9 inhibitors; statins |
| Description | First line drug for the treatment of hypercholesterolemia are statins, which reduce LDL-cholesterol up to 50 %; such reduction is sufficient for most patients to achieve the target values. The exceptions are patients with familial hypercholesterolemia and patients with statin intolerance. To achieve target LDL-cholesterol in these two groups of patients will be possible with new drugs – PCSK9 inhibitors, which decrease LDL-cholesterol by an additional 50–60 %. The first two PCSK9 inhibitors (alirocumab and evolocumab) already had been approved for clinical use by European regulatory authorities. The primary indication for combination statin with PCSK9 inhibitor should be undoubtedly patients with a confirmed diagnosis of familial hypercholesterolemia, who are treated in the Czech Republic primarily in specialized centers of MedPed project. Furthermore, this treatment should be available for other patients at very high risk of cardiovascular diseases, who cannot achieve target LDL-cholesterol (eg. for statins intolerance). |